Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaMultimorbidity: an issue of growing importance for oncologistsThe impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.Senior adult oncology.Carcinoma of the cervix in elderly patients treated with radiotherapy: patterns of care and treatment outcomesImpact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies.Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Management of Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia in the Accelerated or Blastic Phase.Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor.Serum-tryptase at diagnosis: a novel biomarker improving prognostication in Ph(+) CML.Severe adverse events associated with the use of second-line BCR/ABL tyrosine kinase inhibitors: preferential occurrence in patients with comorbidities.Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program.Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.Firstline treatment for chronic phase chronic myeloid leukemia patients should be based on a holistic approach.Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia.Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.Correlation between Charlson comorbidity index and outcome in patients with chronic phase chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors upfront.
P2860
Q26749324-4DD5583D-56FB-4F1E-BD46-46C6192A6AEBQ35559778-F021A2BB-2460-430F-A3EF-4ADA8060A78CQ35832484-64C2499B-3F59-43AC-9368-BEDE223970D3Q36070796-E92EBC33-8A0B-4965-ACDB-4C4AF0E25470Q36851424-EF0FB020-05FC-479B-86D8-8E5D68360C09Q37364035-D6FD12A5-524E-49A2-84F4-B2E3F66C279CQ38148243-207B7AD0-DC23-4A27-9457-2EF7BCC81D6DQ38202913-C3F97ACF-058B-4466-8F57-A83663635FEFQ38707841-AA06E5F1-C40C-4787-AAA7-BBF651E92327Q38767908-508D59AF-AA0F-4620-8FA5-F7366ED11C0CQ40519438-6DB603AC-3004-4563-8274-90FA6709857EQ41515301-DF3B4769-758C-4DFE-99BA-A29A937853D0Q42930387-92B56FF7-9D88-48C1-88D5-D01577D86418Q44129015-B50F6CD7-4B66-43FA-9FCC-715716880330Q46163359-106F377B-5AAE-497D-BA40-130025740AB5Q47877989-149E30AD-6BF6-4B14-AD67-369B09FEBBFFQ48058725-B7C6936C-A6D9-45F7-A7E1-CCA472A8D384Q50998286-E3F28A7D-3731-4F30-AEB3-4131F5EAC8E8Q51068078-AA01FBAD-9F7D-48BC-A87A-18E11E66AAB9Q53655374-E2642CFA-891C-4DA4-B147-A77592EE9785
P2860
Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Charlson comorbidity index and ...... ed with second-line dasatinib.
@ast
Charlson comorbidity index and ...... ed with second-line dasatinib.
@en
type
label
Charlson comorbidity index and ...... ed with second-line dasatinib.
@ast
Charlson comorbidity index and ...... ed with second-line dasatinib.
@en
prefLabel
Charlson comorbidity index and ...... ed with second-line dasatinib.
@ast
Charlson comorbidity index and ...... ed with second-line dasatinib.
@en
P2093
P2860
P50
P1433
P1476
Charlson comorbidity index and ...... ed with second-line dasatinib.
@en
P2093
Antonella Gozzini
Antonella Russo Rossi
Giovanna Rege-Cambrin
Luigiana Luciano
Mario Annunziata
Patrizia Pregno
Simona Sica
P2860
P304
P356
10.3324/HAEMATOL.2011.041251
P50
P577
2011-06-17T00:00:00Z